Trinity Biotech, the Nasdaq listed Bray medical firm, is to defer its planned share buyback programme until early next year.
The company, headed by chief executive Ronan O’Caoimh, had originally planned to begin the buyback in November but said that the need to clear a number of outstanding legal hurdles meant that the programme was unlikely to proceed before the end of the year.
Speaking after Trinity reported third-quarter earnings figures last week,...
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Unlimited Access for 2 Years
Get a Business Account for you and your team